Brevan Howard Capital Management’s Atrium Therapeutics RNA Stock Holding History
Bought
Maintained
Sold
Other funds holding RNA
Brevan Howard Capital Management's RNA Position: Q3 2026 in Review
Brevan Howard Capital Management sold out of Atrium Therapeutics (RNA) in Q3 2026, closing a stake of 20,834 shares — an estimated $280K sold.
Brevan Howard Capital Management first reported a position in RNA in Q1 2026 and held it in 2 quarters. The position peaked at $423K in Q1 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.
- Brevan Howard Capital Management reported no remaining Atrium Therapeutics position as of Q3 2026 after selling out during the quarter.
- Brevan Howard Capital Management sold 20,834 Atrium Therapeutics shares in Q3 2026, an estimated $280K.
- Brevan Howard Capital Management first reported a position in Atrium Therapeutics in Q1 2026 and held it in 2 quarters.
- Brevan Howard Capital Management's Atrium Therapeutics position peaked at $423K in Q1 2026.
- 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.
Based on Brevan Howard Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.